Akebia Therapeutics Stock News

The FDA has issued a complete response letter (CRL) to Akebia Therapeutics Inc's (NASDAQ: AKBA) marketing application (NDA) for vadadustat for anemia due to chronic kidney disease (CKD).  Vadadus

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug Pfizer, Inc.

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on Invest

Do Food and Drug Administration decisions—thumbs up or thumbs down—affect the stock prices of companies seeking drug approvals? We're likely to find out this month as several key drugs are about t

Following back-to-back intraday gains, the shares of commercial-stage biotech, Akebia Therapeutics <> have dropped on Friday after JPMorgan highlighted potential regulatory issues…

Penny stocks for your watch list this month. The post 3 Penny Stocks To Watch For Your List In March 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.'s (NASDAQ: AG

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -21.21% and 23.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock

CAMBRIDGE, Mass., March 1, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full-year ended December 31, 2021…

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -21.21% and 23.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock

Under any circumstance, penny stocks are extremely risky. However, their under-the-radar profile could be intriguing right now.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak''s Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences Inc. (Nasdaq: KOD ) announced negative top-line results from its Phase 2b/3 clinical trial evaluating the KSI-301 in treatment-naïve subjects with neovascular age-related macular degeneration. The study did not meet the primary efficacy endpoint of showing non-inferior visual acuity gains for subjects dosed on extended regimens compared to aflibercept given every eight weeks. The stock was sinking 70.86% to $14.67 in premarket trading. Akebia''s Announces Expanded Agreement With Vifor Regarding Marketing Of Its Kidney Disease Drug Akebia Therapeutics, Inc. (NASDAQ: AKBA ) and Vifor Pharma AG (OTC: GNHAF ) announced that the companies have amended and restated the terms of their license agreement. Under the amended agreement Akebia granted Vifor an exclusive license to sell vadadustat, its investigational oral therapeutic for the treatment of anemia due to chronic kidney disease, to Fresenius Medical Care North America, subject to vadadustat''s approval by the U.S.

Akebia Therapeutics (AKBA) amended a license agreement with Vifor Pharma (GNHAF) for the former''s vadadustat, a potential treatment for anemia due to chronic kidney disease.

CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2021…